^
Association details:
| Biomarker: | FGFR3-TACC3 fusion + FGFR3 V555M |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | TYRA-300 (FGFR3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
462P - TYRA-300: FGFR3 selective and gatekeeper agnostic
Published date:
09/05/2022
Excerpt:
In the FGFR3::TACC3-V555M xenograft model, a 77% inhibition of tumor growth was observed with TYRA-300 while a 12% tumor growth inhibition was observed with erdafitinib….TYRA-300 is currently under development for patients with FGFR3-altered urothelial carcinoma. TYRA-300 retains efficacy in the presence of a gatekeeper resistance mutation.
